Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects with Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to see if IMC-3C5 is safe to give to patients and to determine the best dose to give.
Description
The purpose of this study is to see if IMC-3C5 is safe to give to patients and to determine the best dose to give.
Details
| Condition | Solid Tumor |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX3732 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.